Sol-Gel Technologies Ltd.

NASDAQ:SLGL

0.65 (USD) • At close September 18, 2024
Bedrijfsnaam Sol-Gel Technologies Ltd.
Symbool SLGL
Munteenheid USD
Prijs 0.648
Beurswaarde 18,040,582
Dividendpercentage 0%
52-weken bereik 0.334 - 2.37
Industrie Biotechnology
Sector Healthcare
CEO Dr. Alon Seri-Levy
Website https://www.sol-gel.com

An error occurred while fetching data.

Over Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment

Vergelijkbare Aandelen

AVITA Medical, Inc. logo

AVITA Medical, Inc.

RCEL

9.96 USD

ProPhase Labs, Inc. logo

ProPhase Labs, Inc.

PRPH

2.45 USD

Ikena Oncology, Inc. logo

Ikena Oncology, Inc.

IKNA

1.66 USD

IO Biotech, Inc. logo

IO Biotech, Inc.

IOBT

1.16 USD

Assertio Holdings, Inc. logo

Assertio Holdings, Inc.

ASRT

1.3 USD

DarioHealth Corp. logo

DarioHealth Corp.

DRIO

0.9 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)